Dear IPA Affiliate, You will no doubt have heard the wonderful news that MyozymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. from the Belgian production facility has
March 3, 2009
Pompe Program Update from Genzyme
Supply Update In January 2009, Genzyme notified the Pompe community that we were experiencing a temporary constraint in the global
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA
February 27, 2009
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe
Amicus Therapeutics announced today that the Company has suspended enrollment for the Phase 2 clinical trialA research study that tests new treatments or approaches in people. of its investigational drug
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase
February 19, 2009
Genzyme Receives Positive Opinion on Myozyme from CHMP
CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has
February 4, 2009
November 2008 Pompe Program Update 2
Genzyme Pompe Program Update- November 17, 2008 We would like to take this opportunity to provide an important update to
Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval
February 4, 2009
November 2008 Pompe Program Update
Genzyme Program Update November 10th, 2008 Genzyme would like to take this opportunity to provide an update to the Pompe